Life Length Certified by U.S. Federal Government and Receives €3.1 Million From the E.U.

29 Sep, 2016, 09:00 ET from Life Length

BILBAO, Spain, September 29, 2016 /PRNewswire/ --

Life Length has received its certification as a clinical and diagnostic laboratory by the U.S. Federal Government and international ISO 15189 accreditation. It has also been awarded €3.1 million by the European Union Horizon 2020 for its ONCOCHECK project.

Life Length, world leader in telomere diagnostics, announced today that it has been certified by the Center for Medicare and Medicaid Services (CMS), the U.S. Government agency, responsible for overseeing clinical laboratory testing in the United States. It has also received the prestigious international ISO 15189 accreditation, recognized in more than 60 countries for quality diagnostic testing along with the Platinum Accreditation by the certifying body A2LA (American Association for Laboratory Accreditation) which conducted the inspection.

     (Logo: http://photos.prnewswire.com/prnh/20160926/411752LOGO )

Additionally, Life Length has been granted €3.1 million by the European Union to carry out clinical studies of its potentially valuable biomarker in cancer treatment involving 1,200 adults and 300 children suffering from one of multiple types of cancer over the next two years. Life Length will carry out this project in partnership with a number of Spain's most important hospitals. The Horizon 2020 program funds just 8 to 10 projects per year and receives thousands of proposals from companies throughout Europe.

These licenses and the ONCOCHECK project confirm that Life Length's proprietary Telomere Analysis Technology® (TAT®) test is accredited for diagnostic use in clinical practice and meets the highest standards of accuracy, reproducibility and quality for use by physicians and pharma clients in all fields from preventive medicine to oncology.

Stephen J. Matlin, CEO of Life Length, noted "the awarding of these regulatory licenses and the ONCOCHECK project demonstrates the maturity of the TAT test. This reinforces the application of our telomere testing assay for clinical use as a biomarker of cellular health, for determining biological age and to measure the efficacy of life-style programs as well as in risk stratification and the early detection of chronic and age-related diseases from cardiovascular and metabolic diseases to cancer. This confirms that Life Length is unquestionably the global leader in this emerging field of life sciences."

About Life Length 

For more information, please visit http://www.lifelength.com .

SOURCE Life Length